Market Overview

Nephros Receives 510(k) Clearance for Hemodiafiltration System


Nephros, Inc. (OTC: NEPH) today announced the Company has received 510(k) clearance from the Food and Drug Administration to market its Hemodiafiltration system for the treatment of chronic renal failure when used with UF controlled dialysis machines capable of producing ultrapure dialysate in accordance with current AAMI/ANSI/ISO standards in the United States.

Posted-In: News FDA


Related Articles (NEPH)

View Comments and Join the Discussion!

Partner Center